BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology 2020;71:334-45. [PMID: 31342529 DOI: 10.1002/hep.30875] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Koshy AN, Farouque O, Calafiore P, Gow PJ. Letter to the Editor: Diagnosis of Cirrhotic Cardiomyopathy: The Role of an Impaired Cardiac Reserve. Hepatology 2020;71:1883-1883. [DOI: 10.1002/hep.31034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Kwon H, Hwang G. Reply. Hepatology 2020;72:784-784. [DOI: 10.1002/hep.31162] [Reference Citation Analysis]
3 Koshy AN, Gow PJ, Testro A, Teh AW, Ko J, Lim HS, Han HC, Weinberg L, VanWagner LB, Farouque O. Relationship between QT interval prolongation and structural abnormalities in cirrhotic cardiomyopathy: A change in the current paradigm. Am J Transplant 2021;21:2240-5. [PMID: 33453141 DOI: 10.1111/ajt.16500] [Reference Citation Analysis]
4 Izzy M, Vanwagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt K, Lee SS; the Cirrhotic Cardiomyopathy Consortium: The Cirrhotic Cardiomyopathy Consortium is a multidisciplinary international group whose focus is to improve the understanding of cirrhotic cardiomyopathy, its management and outcomes. Reply:. Hepatology 2020;71:1884-5. [DOI: 10.1002/hep.31035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kaur H, Premkumar M. Diagnosis and Management of Cirrhotic Cardiomyopathy. Journal of Clinical and Experimental Hepatology 2022;12:186-99. [DOI: 10.1016/j.jceh.2021.08.016] [Reference Citation Analysis]
6 Koshy AN, Gow PJ, Han HC, Teh AW, Jones R, Testro A, Lim HS, McCaughan G, Jeffrey GP, Crawford M, Macdonald G, Fawcett J, Wigg A, Chen JWC, Gane EJ, Munn SR, Clark DJ, Yudi MB, Farouque O. Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. Eur Heart J Qual Care Clin Outcomes 2020;6:243-53. [PMID: 32011663 DOI: 10.1093/ehjqcco/qcaa009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
7 Mechelinck M, Hartmann B, Hamada S, Becker M, Andert A, Ulmer TF, Neumann UP, Wirtz TH, Koch A, Trautwein C, Roehl AB, Rossaint R, Hein M. Global Longitudinal Strain at Rest as an Independent Predictor of Mortality in Liver Transplant Candidates: A Retrospective Clinical Study. J Clin Med 2020;9:E2616. [PMID: 32806645 DOI: 10.3390/jcm9082616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sonny A. Cardiovascular adverse events after liver transplantation: a long road ahead for improvement. Eur Heart J Qual Care Clin Outcomes 2020;6:227-8. [PMID: 32275746 DOI: 10.1093/ehjqcco/qcaa031] [Reference Citation Analysis]
9 Sharma S, Sonny A, Dalia AA, Karamchandani K. Acute heart failure after liver transplantation: A narrative review. Clin Transplant 2020;34:e14079. [PMID: 32941661 DOI: 10.1111/ctr.14079] [Reference Citation Analysis]
10 Toma L, Stanciu AM, Zgura A, Bacalbasa N, Diaconu C, Iliescu L. Electrocardiographic Changes in Liver Cirrhosis-Clues for Cirrhotic Cardiomyopathy. Medicina (Kaunas) 2020;56:E68. [PMID: 32050594 DOI: 10.3390/medicina56020068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Philips CA, Kakkar K, Joseph M, Yerol PK, Ahamed R, Rajesh S, Augustine P. Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. J Clin Transl Hepatol 2021;9:576-86. [PMID: 34447688 DOI: 10.14218/JCTH.2020.00110] [Reference Citation Analysis]
12 Cesari M, Frigo AC, Piano S, Angeli P. Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. Clin Exp Hepatol 2021;7:270-7. [PMID: 34712828 DOI: 10.5114/ceh.2021.108708] [Reference Citation Analysis]
13 Kwon HM, Jang HY, Hwang GS. REPLY. Hepatology 2021;74:536-7. [PMID: 33459369 DOI: 10.1002/hep.31722] [Reference Citation Analysis]
14 Koshy AN, Gow PJ, Farouque O. Cirrhotic Cardiomyopathy: An Evolving Diagnostic Entity With Long-Term Clinical Sequelae. Liver Transpl 2021;27:794-6. [PMID: 33683815 DOI: 10.1002/lt.26046] [Reference Citation Analysis]
15 Bonavia A, Vece G, Karamchandani K. Prerenal acute kidney injury—still a relevant term in modern clinical practice? Nephrology Dialysis Transplantation 2021;36:1570-7. [DOI: 10.1093/ndt/gfaa061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Alvarado-Tapias E, Vilades D, Brujats A, Villanueva C. Reply to: "Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link?". J Hepatol 2021;75:993-4. [PMID: 34224780 DOI: 10.1016/j.jhep.2021.06.026] [Reference Citation Analysis]
17 Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol 2021;18:117-35. [PMID: 32999450 DOI: 10.1038/s41569-020-0433-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Mazumder NR, VanWagner LB. QT and outcomes in cirrhosis: A prolonged debate on causality in need of correction. Am J Transplant 2021;21:451-2. [PMID: 32659873 DOI: 10.1111/ajt.16209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Liu H, Lee SS. Diagnostic Criteria of Cirrhotic Cardiomyopathy: Out With the Old, in With the New? Hepatology 2021. [PMID: 34152621 DOI: 10.1002/hep.32021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Koshy AN, Gow PJ, Han HC, Teh AW, Lim HS, Testro A, Jones R, Farouque O. Sudden cardiac death following liver transplantation: Incidence, trends and risk predictors. Int J Cardiol 2021;327:171-4. [PMID: 33253736 DOI: 10.1016/j.ijcard.2020.11.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Koshy AN, Ko J, Farouque O, Cooray SD, Han H, Cailes B, Gow PJ, Weinberg L, Testro A, Lim HS, Teh AW. Effect of QT interval prolongation on cardiac arrest following liver transplantation and derivation of a risk index. Am J Transplant 2021;21:593-603. [DOI: 10.1111/ajt.16145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Izzy M, Lin G, Watt KD. Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link? J Hepatol 2021;75:992-3. [PMID: 33932487 DOI: 10.1016/j.jhep.2021.04.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Aghaulor B, VanWagner LB. Cardiac and Pulmonary Vascular Risk Stratification in Liver Transplantation. Clin Liver Dis 2021;25:157-77. [PMID: 33978576 DOI: 10.1016/j.cld.2020.08.008] [Reference Citation Analysis]
24 Kim KS, Kwon HM, Jung KW, Sang BH, Moon YJ, Kim B, Jun IG, Song JG, Hwang GS. Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant. J Gastroenterol Hepatol 2021;36:758-66. [PMID: 32804412 DOI: 10.1111/jgh.15179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Isaak A, Praktiknjo M, Jansen C, Faron A, Sprinkart AM, Pieper CC, Chang J, Fimmers R, Meyer C, Dabir D, Thomas D, Trebicka J, Attenberger U, Kuetting D, Luetkens JA. Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis. Radiology 2020;297:51-61. [PMID: 32808886 DOI: 10.1148/radiol.2020201057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
27 Thevenot T, Mouhat B, Revel L, Altieri M. The Evaluation of Cirrhotic Cardiomyopathy in Liver Transplantation Candidates: An Emerging Debate. Liver Transpl 2021;27:1068-9. [PMID: 33660905 DOI: 10.1002/lt.26038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Truby LK, Mentz RJ, Agarwal R. Cardiovascular risk stratification in the noncardiac solid organ transplant candidate. Curr Opin Organ Transplant 2022;27:22-8. [PMID: 34939961 DOI: 10.1097/MOT.0000000000000942] [Reference Citation Analysis]
29 Baiges A, Garcia-Pagán JC. Predicting Heart Failure After TIPS: Still More Questions Than Answers. Hepatology 2019;70:1889-91. [PMID: 31520412 DOI: 10.1002/hep.30948] [Reference Citation Analysis]
30 Pimentel CFMG, Amaral ACC, Gonzalez AM, Lai M, Mota DO, Ferraz MLG, Junior WM, Kondo M. Six-minute walking test performance is associated with survival in cirrhotic patients. World J Hepatol 2021; 13(11): 1791-1801 [PMID: 34904046 DOI: 10.4254/wjh.v13.i11.1791] [Reference Citation Analysis]
31 Kakar P, Gubitosa J, Gerula C. Echocardiography in the Liver Transplant Patient. Curr Cardiol Rep 2021;23:110. [PMID: 34216273 DOI: 10.1007/s11886-021-01531-1] [Reference Citation Analysis]
32 Yoon KT, Liu H, Lee SS. Cirrhotic Cardiomyopathy. Curr Gastroenterol Rep 2020;22:45. [PMID: 32651721 DOI: 10.1007/s11894-020-00783-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
33 Levy PE, Khan SS, VanWagner LB. Cardiac evaluation of the kidney or liver transplant candidate. Curr Opin Organ Transplant 2021;26:77-84. [PMID: 33315765 DOI: 10.1097/MOT.0000000000000838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Barman PM, Chadha RM, VanWagner LB. Cardiac Risk Assessment in Liver Transplant Candidates: A Survey of National Practice Patterns. Liver Transpl 2021. [PMID: 34536331 DOI: 10.1002/lt.26307] [Reference Citation Analysis]
35 Kasper P, Steffen HM, Michels G. [Cirrhotic cardiomyopathy]. Dtsch Med Wochenschr 2021;146:1070-6. [PMID: 34416775 DOI: 10.1055/a-1321-9523] [Reference Citation Analysis]
36 Li M, Guo Z, Zhang D, Xu X, Romeiro FG, Mancuso A, Zhang J, Feng R, Zhou X, Hong C, Qi X. Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis. Gastroenterol Res Pract 2020;2020:4019289. [PMID: 33029132 DOI: 10.1155/2020/4019289] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
38 Barman PM, VanWagner LB. Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions. Hepatology 2021;73:2564-76. [PMID: 33219576 DOI: 10.1002/hep.31647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Reference Citation Analysis]
40 Izzy MJ, VanWagner LB. Current Concepts of Cirrhotic Cardiomyopathy. Clin Liver Dis 2021;25:471-81. [PMID: 33838862 DOI: 10.1016/j.cld.2021.01.012] [Reference Citation Analysis]
41 Bodys-Pełka A, Kusztal M, Raszeja-Wyszomirska J, Główczyńska R, Grabowski M. What's New in Cirrhotic Cardiomyopathy?-Review Article. J Pers Med 2021;11:1285. [PMID: 34945757 DOI: 10.3390/jpm11121285] [Reference Citation Analysis]
42 Zardi EM, Giorgi C, Dobrina A, Vecile E, Zardi DM. Analogies and differences between cirrhotic cardiomyopathy and hepatopulmonary syndrome. Med Res Rev 2021;41:739-53. [PMID: 33174630 DOI: 10.1002/med.21755] [Reference Citation Analysis]
43 Matyas C, Erdelyi K, Trojnar E, Zhao S, Varga ZV, Paloczi J, Mukhopadhyay P, Nemeth BT, Haskó G, Cinar R, Rodrigues RM, Ait Ahmed Y, Gao B, Pacher P. Interplay of Liver-Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy. Hepatology 2020;71:1391-407. [PMID: 31469200 DOI: 10.1002/hep.30916] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
44 Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, Watt KD. Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria. Liver Transpl 2021;27:876-86. [PMID: 33533556 DOI: 10.1002/lt.26000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
45 Izzy M, Lin G, Watt KD. Cirrhotic cardiomyopathy prevalence according to the new criteria. Liver Int 2021;41:1170. [PMID: 33595171 DOI: 10.1111/liv.14826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Marella HK, Kamal F, Peravali R, Jacob J, Nair SP. Left ventricular diastolic dysfunction in liver transplantation: a stronger association with non-alcoholic steatohepatitis. Clin Exp Hepatol 2020;6:158-62. [PMID: 32728634 DOI: 10.5114/ceh.2020.95893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Kwon HM, Moon YJ, Kim KS, Shin WJ, Huh IY, Jun IG, Song JG, Hwang GS. Prognostic Value of B-Type Natriuretic Peptide in Liver Transplant Patients: Implication in Posttransplant Mortality. Hepatology 2021;74:336-50. [PMID: 33249627 DOI: 10.1002/hep.31661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Lu X, Wang Z, Yang L, Yang C, Song M. Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study. Front Cardiovasc Med 2021;8:704073. [PMID: 34291096 DOI: 10.3389/fcvm.2021.704073] [Reference Citation Analysis]
49 Wiese S, Voiosu A, Hove JD, Danielsen KV, Voiosu T, Grønbaek H, Møller HJ, Genovese F, Reese-Petersen AL, Mookerjee RP, Clemmesen JO, Gøtze JP, Andersen O, Møller S, Bendtsen F. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther 2020;52:340-50. [PMID: 32524673 DOI: 10.1111/apt.15812] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
50 Sessa A, Allaire M, Lebray P, Medmoun M, Tiritilli A, Iaria P, Cadranel JF. From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management? JHEP Rep 2021;3:100249. [PMID: 33665589 DOI: 10.1016/j.jhepr.2021.100249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
51 Liu H, Yoon KT, Zhang J, Lee SS. Advances in cirrhotic cardiomyopathy. Curr Opin Gastroenterol 2021;37:187-93. [PMID: 33756518 DOI: 10.1097/MOG.0000000000000733] [Reference Citation Analysis]
52 von Köckritz F, Braun A, Schmuck RB, Dobrindt EM, Eurich D, Heinzel FR, Pieske B, Escher F, Zhang K. Speckle Tracking Analysis Reveals Altered Left Atrial and Ventricular Myocardial Deformation in Patients with End-Stage Liver Disease. J Clin Med 2021;10:897. [PMID: 33668295 DOI: 10.3390/jcm10050897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Zhang Y, Fang XM. Hepatocardiac or Cardiohepatic Interaction: From Traditional Chinese Medicine to Western Medicine. Evid Based Complement Alternat Med 2021;2021:6655335. [PMID: 33777158 DOI: 10.1155/2021/6655335] [Reference Citation Analysis]
54 Ma L, Liu X, Wu Q, Hu X, Liu H, Zhang J, Lee SS. Role of Anti-Beta-1-Adrenergic Receptor Antibodies in Cardiac Dysfunction in Patients with Cirrhotic Cardiomyopathy. J Cardiovasc Transl Res 2021. [PMID: 34417673 DOI: 10.1007/s12265-021-10161-5] [Reference Citation Analysis]
55 Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]